Compare Medtronic PLC (MDT) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

QVCAQ trades at $0.05, down 14.68% today, reflecting severe financial distress with negative equity and consecutive annual losses. The stock shows a bearish technical signal, with most moving averages indicating sell pressure. Recent cash flow improvements stem from financing activities, not operations. The company celebrated 40 years of innovation with a TikTok Shop event, but fundamentals remain weak.

Outlook is highly risky due to persistent net losses, declining revenue, and negative shareholder equity. Investment opportunity is minimal without a turnaround in profitability. Key risks include high debt burden, competitive pressures in retail, and inability to achieve sustained earnings growth. Investors should avoid until operational stability is demonstrated.